According to reports from Business Standard and Storyboard18, Cipla announced that its wholly owned subsidiary, Cipla Health, has appointed Shivam Puri as chief executive officer (CEO) of its One India Business and a member of the company's Management Council, effective 1 July 2026. Puri, who currently serves as managing director (MD) and CEO of Cipla Health, will also be designated as a Senior Management Personnel of the company. The appointment is on a full-time employment basis, as reported in the regulatory filing. Cipla emphasized that Puri brings over two decades of FMCG and healthcare leadership experience with strong commercial acumen and consumer-centric expertise.
As reported by Business Standard and Storyboard18, Puri has been leading Cipla Health since 2019 and has played a key role in expanding its consumer healthcare and wellness portfolio across categories such as smoking cessation, pain care, cough and cold, skincare, haircare and nutrition. Under his leadership, the business evolved from a startup venture into one of India's leading wellness-focused consumer goods companies. He brings more than 23 years of leadership experience across the FMCG and healthcare sectors, having held senior leadership positions at Hindustan Unilever Ltd, Jubilant FoodWorks Ltd and ITC Ltd. The appointment signals a strategic effort to bring consumer-focused growth expertise into Cipla's largest market, as the company seeks to expand beyond traditional prescription medicines into wellness, preventive care and consumer health products.
According to Business Standard and Storyboard18, Puri holds a Bachelor of Technology degree from IIT (BHU) Varanasi and an MBA from the Indian Institute of Management (IIM), Lucknow. During his tenure at Hindustan Unilever, he managed multiple businesses, including the Pureit water purifier portfolio, homecare division and modern trade operations, besides overseeing brands such as Surf Excel. His more than 15-year stint at Hindustan Unilever provided extensive commercial and consumer-focused expertise that will now steer Cipla's domestic operations. The promotion reflects a wider trend among healthcare companies that are borrowing strategies from fast-moving consumer goods businesses to deepen patient engagement, strengthen brand recognition and expand market reach.
According to The Economic Times and Storyboard18, Cipla's board also approved grants under its employee stock compensation plans as part of the leadership announcement. The company granted 11,360 stock options under the Employee Stock Option Scheme 2013-A and 51,394 employee stock appreciation rights under the Employee Stock Appreciation Rights Scheme 2021. The stock options will vest after two years from the grant date and can be exercised within five years of vesting, while the ESARs will vest over three years on a graded basis and will remain exercisable for five years from vesting. Both were granted at an exercise price of ₹2 each.
As reported by Storyboard18, the leadership transition comes as companies across the pharmaceutical sector seek to strengthen their domestic franchises while navigating pricing pressures, regulatory scrutiny and intensifying competition. Industry analysts have increasingly pointed to the convergence of healthcare and consumer wellness as a major growth theme in India, where rising incomes, greater health awareness and increased spending on preventive care are reshaping demand patterns. For Cipla, one of India's largest pharmaceutical manufacturers, the appointment reflects the company's strategic focus on applying consumer-centric approaches across its broader domestic operations, positioning it to capitalize on the growing wellness market while maintaining its pharmaceutical expertise.
